Author

James A McGrory

Observed names: J McGrory, James A. McGrory, James McGrory

Institution: Alkermes (United States)

Observed institution: Alkermes (United States)

ORCID: 0000-0003-0906-023X

Observed ORCID: 0000-0003-0906-023X

OpenAlex ID: A5039183024

Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia

2025 · Leslie Citrome, Christoph Correll, et al. · Neuropsychiatric Disease and Treatment · 8

Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic

2023 · Batool Haider, Amy K O'Sullivan, et al. · Neuropsychiatric Disease and Treatment · 4

Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen in Patients with Schizophrenia

2025 · John Lauriello, Michael J. Doane, et al. · Advances in Therapy · 3

Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”

2022 · Bhaskar Rege, James McGrory, et al. · PharmacoEconomics · 2

Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia

2025 · Peter Weiden, Lauren Strand, et al. · Neuropsychiatric Disease and Treatment · 1

Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc Analysis.

2024 · Mark G A Opler, Amy Claxton, et al. · PubMed Central · 1

Comment on “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use”

2023 · Daniel Still, Kathy Do, et al. · Mental Health Clinician · 1

Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial

2025 · Leslie Citrome, Martin Dunbar, et al. · Neuropsychiatric Disease and Treatment

Aripiprazole Lauroxil Every 2 Months for the Treatment of Adults With Schizophrenia: A Post Hoc Analysis of Efficacy by Baseline Severity of Illness From Phase 3b Clinical Trial Data

2025 · John M Kane, James A McGrory · Schizophrenia Bulletin Open

RWD103 Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen

2024 · L Strand, M Doane, et al. · Value in Health

CO122 Patient Versus Caregiver and Clinician Reports of Cognitive Difficulties in Patients with Schizophrenia Switching to Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: A Post Hoc Analysis

2022 · MGA Opler, A Claxton, et al. · Value in Health

Works count: 11

Citation count: 20

H-index: 3

I10-index: